InvestorsHub Logo
Followers 39
Posts 7292
Boards Moderated 0
Alias Born 10/17/2013

Re: europtiger post# 744

Monday, 12/09/2019 9:04:44 AM

Monday, December 09, 2019 9:04:44 AM

Post# of 777
Pre-Market: $ 0.84 + 0.355 (73,19%)

Patients who received momelotinib had significantly decreased transfusion requirements compared to those treated with ruxolitinib, including a nearly 10-fold higher odds of receiving no transfusions during the 24-week study period (covariate ZINB model; p < 0.0001).